Tag: ASX: CU6
Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has entered into a Master Services Agreement (MSA) and Clinical Manufacturing Agreement for the production of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer.
Clarity Pharmaceuticals inks clinical supply agreement for prostate cancer imaging products
ASX-listed Clarity Pharmaceuticals has signed a Master Service Agreement and a Clinical Supply Agreement with Siemens Healthineers company PETNET Solutions Inc for the supply expansion of Clarity’s 64Cu SAR-bisPSMA, a diagnostic radiopharmaceutical product for prostate cancer imaging.
Featured Article
How growth capital is helping an Australian manufacturer go global
There’s a particular kind of ingenuity that flourishes in regional Australia. Away from the noise of major business centres, founders build companies that quietly become world leaders in their field, solving deep specialised problems that global markets didn’t know could be solved. Modra Technology, based in Warragul in regional Victoria, is one of those companies.
